Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa

Table 2

Demographic databases of patients in clinical remission, clinical response, and failure after IFX induction therapy.

Variable	Remission group; ( = 61)	Response group; ( = 17)	Failure group; ( = 28)	value
Age of diagnosis, yrs	27.3 ± 8.5	25.6 ± 9.4	28.0 ± 12.4	0.72
A1 (≤16)	5	2	3	0.99
A2 (17–40)	50	13	22
A3 (>40)	6	2	3
Gender, male/female	46/15	10/7	21/7	0.38
Disease duration, mths	22.2 ± 23.2; (0.5–96)	44.6 ± 37.9; (3–147.6)	71.0 ± 58.2; (2–192)	<0.0001
Location
L1, (%)	11 18.0	4 23.5	3 10.7	0.03
L2, (%)	7 11.5	7 41.2	8 28.6
L3, (%)	43 70.5	6 35.3	17 60.7
Behavior
B1, (%)	38 62.3	5 29.4	6 21.4	0.0007
B2, (%)	15 24.6	6 35.3	8 28.6
B3, (%)	8 13.1	6 35.3	14 50.0
Current smokers, (%)	8 13.1	4 23.5	7 (25)	0.32
Step-up strategy, (%)	26 42.6	13 76.4	18 64.3	0.02
Top-down strategy, (%)	35 57.4	4 23.6	10 35.7